Wave Life Sciences announced the pricing of its underwritten public offering of ordinary shares and pre-funded warrants.
Gross proceeds from the offering expected to be approximately $350 million.
The underwriters granted a 30-day option to purchase additional ordinary shares.
Public Offering Details
Offering of 15,789,475 ordinary shares and pre-funded warrants to purchase up to 2,631,578 ordinary shares.
Underwriters and Managers
Jefferies, Leerink Partners, and BofA Securities act as joint book-running managers for the offering.
Offering Closure
Expected to close on or about December 11, 2025, subject to customary closing conditions.
- Wave Life Sciences aims to utilize the gross proceeds to fund its strategic initiatives and further its research and development activities.
- The offering's success indicates investor confidence in Wave's prospects and potential growth.
- The additional 30-day option to purchase shares provides flexibility to the underwriters and boosts market interest.
With the pricing of the public offering completed, Wave Life Sciences is poised to bolster its financial position and advance its innovative RNA medicines platform.